Professional Seasonal Analysis for Trading

Matinas Biopharma Holdings, Inc. Common Stock (MTNB)

Seasonality Analysis

Stocks 12 Years Analyzed

Matinas Biopharma Holdings, Inc. Common Stock Annual Seasonality Statistics

-3.21%
Avg Annual Return
38.6%
Avg Monthly Win Rate
5/12
Positive Months
12
Years Analyzed

Matinas Biopharma Holdings, Inc. Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January 0.89%
33%
Weak
February 3.01%
50%
Weak
March -6.47%
33%
Very Weak
April -1.67%
33%
Very Weak
May -3.66%
27%
Very Weak
June -5.60%
27%
Very Weak
July WORST -8.82%
17%
Very Weak
August 6.05%
50%
Weak
September BEST 16.18%
50%
Weak
October -4.95%
33%
Very Weak
November 2.06%
67%
Strong
December -0.24%
42%
Weak

Matinas Biopharma Holdings, Inc. Common Stock 2026 vs Historical Pattern

Current Position
15.27
Historical Avg Position
33.49
Deviation
-18.22
Performance
Significantly Below Average

Matinas Biopharma Holdings, Inc. Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for MTNB with overlay patterns, custom date ranges, and more.

Create Free Account

Matinas Biopharma Holdings, Inc. Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Matinas Biopharma Holdings, Inc. Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for MTNB across multiple timeframes.

Create Free Account

About Matinas Biopharma Holdings, Inc. Common Stock (MTNB) Seasonality

Matinas Biopharma Holdings, Inc. Common Stock (MTNB) has been analyzed using 12 years of historical data to identify seasonal patterns. Classified under Stocks, Matinas Biopharma Holdings, Inc. Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Matinas Biopharma Holdings, Inc. Common Stock is historically September, with an average return of 16.18% and a win rate of 50%. Conversely, July tends to be the weakest month, averaging -8.82% return.

Looking at the full calendar year, Matinas Biopharma Holdings, Inc. Common Stock has an average annual return of -3.21% with an overall monthly win rate of 38.6%. Out of 12 months, 5 typically show positive average returns.

The seasonal pattern for Matinas Biopharma Holdings, Inc. Common Stock has a consistency score of 47.7 (Poor), based on 13 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Matinas Biopharma Holdings, Inc. Common Stock Seasonality FAQ

What is the best month to buy Matinas Biopharma Holdings, Inc. Common Stock (MTNB)?

Historically, September has been the best month for Matinas Biopharma Holdings, Inc. Common Stock, with an average return of 16.18% and a win rate of 50%. However, past performance does not guarantee future results.

What is the worst month for Matinas Biopharma Holdings, Inc. Common Stock (MTNB)?

Based on historical data, July has been the weakest month for Matinas Biopharma Holdings, Inc. Common Stock, with an average return of -8.82%. This is a historical observation and does not guarantee future results.

How reliable is MTNB seasonality data?

The seasonality analysis for Matinas Biopharma Holdings, Inc. Common Stock is based on 12 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Matinas Biopharma Holdings, Inc. Common Stock seasonality in my trading?

Use Matinas Biopharma Holdings, Inc. Common Stock (MTNB) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.